Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal
A phase 3 trial of Sotorasib, Panitumumab in colorectal cancer, run by Amgen, now recruiting.
Overview
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation is a phase 3 interventional study registered as NCT06252649 by Amgen, with 450 participants planned, started 2024-07-17 and due to reach its primary completion in 2028-09-25. Interventions recorded: FOLFIRI Regimen, Sotorasib, Panitumumab, Bevacizumab-awwb. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Shares Panitumumab, Sotorasib, Amgen.
- TrialA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants Wi
- TrialCodeBreaK 300
Shares Panitumumab, Sotorasib, Colorectal cancer.
- TrialA Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Shares Panitumumab, Colorectal cancer.
- TrialA Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,
Shares Panitumumab, Colorectal cancer.
- PairingAnti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC
Shares Panitumumab, Colorectal cancer.
- TrialPARADIGM
Shares Panitumumab, Colorectal cancer.
- TreatmentTempus xT CDx
Shares Panitumumab, Colorectal cancer.